ExpreS2ion Biotech Holding AB (EXPRS2) Stock Price & Analysis

EXPRS2 Stock Chart & Stats

SEK 0.93SEK 0.00(0.00%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: SEK 0.93 - SEK 0.95
52-Week Range: SEK 0.88 - SEK 6.98
Previous Close: SEK 0.93
Volume: 135
Average Volume (3M): 85.95K
Market Cap: SEK 36.86M
Enterprise Value: SEK 22.17M
Total Cash (Recent Filing): SEK 34.38M
Total Debt (Recent Filing): SEK 1.45M
Price to Earnings (P/E): ―
Beta: 1.19
Next Earnings: Nov 12, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage reduces refinancing pressure and limits interest-related strain on the business. This gives ExpreS2ion greater financial flexibility than a heavily indebted biotechnology company while it works to improve profitability and fund development activities.

Platform-based Business Model

The company can monetize the same expression technology through fee-based services, technology access, and collaborations. This creates multiple potential routes to commercial income and allows the platform to serve research, diagnostics, and biopharmaceutical development markets.

Recent Revenue Improvement

Recent top-line improvement indicates some progress in commercial activity despite the company’s early-stage economics. If sustained, revenue growth could improve operating leverage over time by spreading the existing platform and operating base across a larger customer and project volume.

Bears Say

Persistent Unprofitable Operations

Negative gross profit and substantial operating losses show that current revenue does not cover the cost base. Continued losses weaken the evidence for an economically scalable model and may require management to pursue significant improvements in pricing, volume, or operating efficiency.

Sustained Cash Burn

Ongoing negative operating and free cash flow means the company is consuming cash to fund its operations rather than internally financing growth. Continued deterioration raises the likelihood of external financing needs, which can constrain strategy and increase dilution or funding pressure.

Eroding Capital Base

Declining equity alongside strongly negative returns indicates that accumulated losses are eroding the company’s capital base. Even with low leverage, further deterioration could reduce financial resilience and increase reliance on new funding to maintain operations and development programs.

EXPRS2 FAQ

What was ExpreS2ion Biotech Holding AB’s price range in the past 12 months?

ExpreS2ion Biotech Holding AB lowest stock price was kr 0.88 and its highest was kr 6.98 in the past 12 months.

What is ExpreS2ion Biotech Holding AB’s market cap?

ExpreS2ion Biotech Holding AB’s market cap is kr 36.86M.

When is ExpreS2ion Biotech Holding AB’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were ExpreS2ion Biotech Holding AB’s earnings last quarter?

ExpreS2ion Biotech Holding AB released its earnings results on Aug 20, 2026. The company reported -kr 0.269 earnings per share for the quarter.

Is ExpreS2ion Biotech Holding AB overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does ExpreS2ion Biotech Holding AB pay dividends?

ExpreS2ion Biotech Holding AB does not currently pay dividends.

What is ExpreS2ion Biotech Holding AB’s EPS estimate?

ExpreS2ion Biotech Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ExpreS2ion Biotech Holding AB have?

ExpreS2ion Biotech Holding AB has 39,468,700 shares outstanding.

What happened to ExpreS2ion Biotech Holding AB’s price movement after its last earnings report?

ExpreS2ion Biotech Holding AB reported an EPS of -kr 0.269 in its last earnings report. Following the earnings report the stock price went down -0.717%.

Which hedge fund is a major shareholder of ExpreS2ion Biotech Holding AB?

Currently, no hedge funds are holding shares in SE:EXPRS2

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description